$1.70
+0.10 (+6.25%)
Open$1.61
Previous Close$1.60
Day High$1.72
Day Low$1.58
52W High$3.10
52W Low$1.33
Volume—
Avg Volume506.9K
Market Cap171.71M
P/E Ratio—
EPS$-0.40
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+441.2% upside
Current
$1.70
$1.70
Target
$9.20
$9.20
$6.27
$9.20 avg
$10.38
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 15.68M | 10.42M | 53.79M |
| Net Income | -40,452,130 | -24,198,681 | 2.31M |
| Profit Margin | -258.1% | -245.2% | 4.3% |
| EBITDA | -39,411,788 | -24,886,140 | 4.13M |
| Free Cash Flow | — | — | 1.88M |
| Rev Growth | +50.5% | +50.5% | +4.8% |
| Debt/Equity | 0.32 | 0.32 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |